Related Experiment Video
Updated: Jan 21, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
4.2K
S-ICD in Hypertrophic Cardiomyopathy: Fewer Complications Without Increased Inappropriate Shocks Versus Transvenous
Christopher Monkhouse1,2, James Malcolmson1,2, Edward Maclean1,2
1Barts Heart Centre, West Smithfield, London, UK.
Pacing and Clinical Electrophysiology : PACE
|January 19, 2026
Summary
Subcutaneous implantable cardioverter defibrillators (S-ICD) show fewer complications in hypertrophic cardiomyopathy (HCM) patients compared to transvenous ICDs (TV-ICD). Multi-event analysis confirms reduced cumulative complication risk with S-ICDs, offering a potentially better benefit/risk ratio.
Area of Science:
- Cardiology
- Medical Devices
- Biomedical Engineering
Background:
- Hypertrophic cardiomyopathy (HCM) patients face long-term risks with implantable cardioverter defibrillators (ICDs), including complications and inappropriate therapy (IT).
- Subcutaneous ICDs (S-ICDs) eliminate vascular risks of transvenous ICDs (TV-ICDs), but IT rates remain a concern.
- Assessing cumulative complication risk is crucial for optimizing ICD selection in HCM.
Purpose of the Study:
- To compare complication rates and cumulative risk between S-ICDs and TV-ICDs in HCM patients.
- To evaluate the impact of device type on therapy rates and mortality.
- To provide a novel assessment of cumulative complication burden using multi-event analysis.
Main Methods:
- Retrospective observational study of 611 HCM patients receiving ICDs (2006-2022).
- Comparative outcome analysis using Cox proportional hazard models and multi-event statistical models.
- Propensity score matching to adjust for baseline differences.
Main Results:
- S-ICD recipients (n=141) experienced significantly fewer complications than TV-ICD recipients (HR 0.309, p=0.035).
- Multi-event analysis revealed a cumulative increase in complications for TV-ICDs (HR 0.258, p=0.004), with no multiple complications in S-ICD patients.
- No significant differences in therapy rates or mortality were observed between matched groups.
Conclusions:
- S-ICDs are associated with fewer complications compared to TV-ICDs in HCM patients, a finding amplified by multi-event analysis.
- Despite similar inappropriate therapy rates, S-ICDs may offer an improved benefit/risk ratio.
- Shared decision-making regarding S-ICD use should be encouraged for HCM patients.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
418
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
418
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
590
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
590
01:30Cardiomyopathy II: Dilated Cardiomyopathy
489
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
489
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
481
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
481
01:25Cardiomyopathy I: Introduction and Classification
517
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
517
01:29Cardiomyopathy VI: Nursing Management
318
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
318